(Credit: Shutterstock)
April 21, 2022 02:04 PM EDTUpdated 04:30 PM
Pharma
Marketing

Crowd­ed rheuma­toid arthri­tis cat­e­go­ry gets JAK re­al­i­ty check, while TNF stal­warts con­tin­ue to dom­i­nate: study

Beth Snyder Bulik

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

RFK Jr. ends an­nu­al Covid vac­cine rec­om­men­da­tions for kids, preg­nant women

Bio­gen taps City Ther­a­peu­tics in RNAi deal worth up to $1B

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times